Log in
(Ad)
In early 2019 President Trump warned this company's biggest customers to "step up their 5G efforts." A few months later, he banned their biggest competitor from doing business in the U.S. Now, this $5 stock could turn a $10,000 stake into $234,770 this year. But timing is critical. A single mention on the evening news and this opportunity could get away from you.

NASDAQ:PULM - Pulmatrix Stock Price, Forecast & News

$1.63
+0.08 (+5.16 %)
(As of 01/20/2020 02:26 AM ET)
Today's Range
$1.50
Now: $1.63
$1.70
50-Day Range
$0.82
MA: $1.07
$1.63
52-Week Range
$0.61
Now: $1.63
$3.01
Volume1.17 million shs
Average Volume2.53 million shs
Market Capitalization$32.60 million
P/E RatioN/A
Dividend YieldN/A
Beta1.32
Pulmatrix, Inc, a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PULM
CUSIPN/A
Phone781-357-2333

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150,000.00
Book Value$2.32 per share

Profitability

Net Income$-20,560,000.00

Miscellaneous

Employees22
Market Cap$32.60 million
Next Earnings Date2/18/2020 (Estimated)
OptionableOptionable

Receive PULM News and Ratings via Email

Sign-up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


A U.S. congressional committee passed important legislation that enables each state to set its own policies around cannabis… This bill also allows states to expunge federal marijuana convictions and arrests. This will likely lead to federal legalization sooner than expected. Get in early and you just might be the next 'Marijuana Millionaire'...

Pulmatrix (NASDAQ:PULM) Frequently Asked Questions

What is Pulmatrix's stock symbol?

Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."

When did Pulmatrix's stock split? How did Pulmatrix's stock split work?

Pulmatrix shares reverse split on Wednesday, February 6th 2019. The 1-10 reverse split was announced on Tuesday, February 5th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 5th 2019. An investor that had 100 shares of Pulmatrix stock prior to the reverse split would have 10 shares after the split.

How were Pulmatrix's earnings last quarter?

Pulmatrix Inc (NASDAQ:PULM) announced its quarterly earnings data on Friday, November, 1st. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.34) by $0.16. The biotechnology company had revenue of $1.41 million for the quarter. View Pulmatrix's Earnings History.

When is Pulmatrix's next earnings date?

Pulmatrix is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Pulmatrix.

What price target have analysts set for PULM?

1 analysts have issued twelve-month price objectives for Pulmatrix's stock. Their forecasts range from $10.00 to $10.00. On average, they expect Pulmatrix's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 513.5% from the stock's current price. View Analyst Price Targets for Pulmatrix.

What is the consensus analysts' recommendation for Pulmatrix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pulmatrix.

Has Pulmatrix been receiving favorable news coverage?

News articles about PULM stock have trended extremely negative this week, according to InfoTrie. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Pulmatrix earned a coverage optimism score of -5.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Pulmatrix.

Are investors shorting Pulmatrix?

Pulmatrix saw a decline in short interest in the month of December. As of December 13th, there was short interest totalling 229,700 shares, a decline of 18.3% from the November 28th total of 281,300 shares. Based on an average daily volume of 122,300 shares, the days-to-cover ratio is presently 1.9 days. Approximately 1.2% of the shares of the company are sold short. View Pulmatrix's Current Options Chain.

Who are some of Pulmatrix's key competitors?

What other stocks do shareholders of Pulmatrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include Cronos Group (CRON), Verastem (VSTM), SCYNEXIS (SCYX), Evoke Pharma (EVOK), Novavax (NVAX), Neovasc (NVCN), Biopharmx (BPMX), Cara Therapeutics (CARA), Rexahn Pharmaceuticals (REXN) and Biocept (BIOC).

Who are Pulmatrix's key executives?

Pulmatrix's management team includes the folowing people:
  • Dr. Robert W. Clarke, CEO, Pres & Director (Age 50)
  • Mr. William E. Duke Jr., CFO, Treasurer & Sec. (Age 47)
  • Dr. James M. Roach, Consultant (Age 59)
  • Dr. Robert S. Langer Jr., Founder & Member of Scientific Advisory Board (Age 70)
  • Prof. David A. Edwards, Founder & Member of Scientific Advisory Board (Age 58)

How do I buy shares of Pulmatrix?

Shares of PULM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pulmatrix's stock price today?

One share of PULM stock can currently be purchased for approximately $1.63.

How big of a company is Pulmatrix?

Pulmatrix has a market capitalization of $32.60 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-20,560,000.00 in net income (profit) each year or ($4.98) on an earnings per share basis. Pulmatrix employs 22 workers across the globe.View Additional Information About Pulmatrix.

What is Pulmatrix's official website?

The official website for Pulmatrix is http://www.pulmatrix.com/.

How can I contact Pulmatrix?

Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-357-2333 or via email at [email protected]


MarketBeat Community Rating for Pulmatrix (NASDAQ PULM)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  160 (Vote Outperform)
Underperform Votes:  117 (Vote Underperform)
Total Votes:  277
MarketBeat's community ratings are surveys of what our community members think about Pulmatrix and other stocks. Vote "Outperform" if you believe PULM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PULM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel